Incorrect password
evipedia.ai Suggest Edit

L-Ergothioneine for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: Ergothioneine, EGT, ERGO, ET, Erythrothioneine, Thiasine, 2-Mercaptohistidine Trimethylbetaine, (S)-2-(Trimethylammonio)-3-(2-thio-1H-imidazol-4-yl)propanoate

Motivation

L-Ergothioneine is a naturally occurring sulfur-containing amino acid that humans cannot manufacture and must obtain from food, primarily mushrooms. The body retains it through a dedicated transporter and concentrates it in tissues that face the highest oxidative load — red blood cells, liver, kidneys, the lens, and brain. Because it is selectively retained, dietarily limited, and declines in the bloodstream after age sixty, it has been proposed as a candidate “longevity vitamin.”

Interest in L-Ergothioneine has shifted from a laboratory curiosity to an active translational topic over the last decade. Observational data link low blood levels to faster cognitive decline, frailty, and all-cause mortality, and the first long-duration human supplementation trials in older adults have begun to report cognitive and biomarker signals.

This review examines what is currently established and what remains uncertain about supplemental L-Ergothioneine for health- and longevity-oriented adults: the use cases the human evidence supports, the dose ranges studied, and the safety profile across animal and short-term human data.

Benefits - Risks - Protocol - Conclusion

This section curates accessible, high-level expert content that introduces L-Ergothioneine, its proposed role as a “longevity vitamin,” and its mushroom-derived dietary biology.

  • Discover the Secret Nutrient That Supports Healthy Aging - Martha McCulloch

    A consumer-facing long-form overview explaining what L-Ergothioneine is, why blood levels fall after age sixty, and how observational data and short human trials connect it to cognitive, cardiometabolic, sleep, and skin outcomes — pitched at the supplement-user audience.

  • 10 Potential “Longevity Vitamins” Including Ergothioneine, PQQ, Queuine, Taurine, Lutein, Zeaxanthin, Astaxanthin & More - Rhonda Patrick

    Rhonda Patrick’s FoundMyFitness summary of Bruce Ames’s “longevity vitamins” framework, placing L-Ergothioneine alongside PQQ, queuine, taurine, and several carotenoids as nutrients whose modest deficiency may insidiously accelerate diseases of aging without producing any classical short-term deficiency syndrome.

  • Prolonging Healthy Aging: Longevity Vitamins and Proteins - Ames, 2018

    The original PNAS narrative review in which Bruce Ames formalized the “longevity vitamins” hypothesis and named L-Ergothioneine as a candidate. The conceptual basis for nearly all subsequent supplementation discussion of L-Ergothioneine in the longevity community.

  • The Nutritional and Therapeutic Health Benefits of Mushrooms, with Jeff Chilton - Chris Kresser

    A long-form podcast in which Chris Kresser and mycologist Jeff Chilton discuss L-Ergothioneine in the context of edible mushrooms — which species are richest, how mycelium-on-grain “mushroom” supplements often contain little to no L-Ergothioneine, and how cooking and soil practices affect dietary content.

  • Ergothioneine and Its Prospects as an Anti-Ageing Compound - Apparoo et al., 2022

    An Experimental Gerontology narrative review covering L-Ergothioneine’s antioxidant, anti-senescence, anti-inflammatory, and anti-neurodegenerative properties, and integrating evidence on its interaction with insulin/IGF, SIRT6, and mTOR signaling — the most accessible academic synthesis of the longevity mechanism case.

Note: Peter Attia and Andrew Huberman have no dedicated public-facing pieces on L-Ergothioneine identified in this search; references on their platforms are limited to passing mentions of mushroom antioxidants. To respect the one-item-per-source rule, only one Rhonda Patrick / FoundMyFitness item is included even though her premium “Aliquot #106” episode also covers the topic.

Grokipedia

Ergothioneine

A comprehensive encyclopedic entry covering L-Ergothioneine’s chemistry as a histidine-derived thione/thiol, microbial biosynthesis, OCTN1 (organic cation/carnitine transporter 1, the dedicated cell-membrane importer of L-Ergothioneine)-mediated transport, mitochondrial localization, dietary sources (porcini, oyster, shiitake mushrooms), and the human trial evidence including the 2025 Zajac dose-response study in older adults.

Examine

Examine.com does not host a dedicated supplement monograph for L-Ergothioneine.

ConsumerLab

Ergothioneine Safety and Use for Preventing Age-Related Problems

ConsumerLab’s member-facing answer page summarizes the studies of L-Ergothioneine for cognitive impairment, dementia, Alzheimer’s disease, Parkinson’s disease, cataract, and kidney disease, along with safety and cost information for supplements and dietary sources such as shiitake, lion’s mane, and reishi mushrooms.

Systematic Reviews

This section presents the systematic reviews and meta-analyses identified through PubMed that bear on L-Ergothioneine and on the closest dietary proxy, mushroom intake.

The PubMed search retrieved no additional systematic reviews or meta-analyses indexed as such for L-Ergothioneine itself as of April 2026. The narrative reviews by Apparoo 2022, Beelman 2022, Chen 2024, Halliwell 2023, and May-Zhang 2025 are referenced elsewhere in this document but do not meet the systematic review or meta-analysis criterion for inclusion in this section.

Mechanism of Action

L-Ergothioneine is not synthesized by humans; it must be obtained from the diet. Its biological role is best described as a selectively retained, low-redox-potential cytoprotectant rather than a classical signaling molecule.

Histidine-derived thione/thiol antioxidant. L-Ergothioneine is 2-mercaptohistidine trimethylbetaine, a histidine derivative whose imidazole ring carries a sulfur atom that exists in a thione/thiol tautomer at physiological pH. The thione form predominates and is unusually resistant to autoxidation, with a redox potential of approximately −0.06 V. This stability allows accumulation in tissues without being consumed by ambient oxidative reactions, distinguishing L-Ergothioneine from glutathione (GSH (glutathione, the cell’s principal soluble thiol antioxidant)) and N-acetylcysteine.

Selective uptake via OCTN1/SLC22A4. Cellular uptake is mediated by the ETT (ergothioneine transporter, the dedicated solute carrier specific for L-Ergothioneine), encoded by SLC22A4 (also called OCTN1 (organic cation/carnitine transporter 1, the membrane protein that imports L-Ergothioneine)). Tissues that express OCTN1 abundantly — bone marrow erythroid cells, liver, kidneys, ocular lens, seminal fluid, and selected brain regions — accumulate L-Ergothioneine to micromolar to millimolar concentrations. Tissues lacking the transporter retain only minimal amounts.

Reactive species scavenging and metal chelation. L-Ergothioneine scavenges hydroxyl radicals, hypochlorous acid, peroxynitrite (ONOO⁻, a strong oxidant formed from superoxide and nitric oxide), singlet oxygen, and to a lesser extent hydrogen peroxide. It chelates pro-oxidant transition metals such as iron and copper, reducing Fenton-reaction radical generation. Its position alongside glutathione gives it complementary reach into compartments where GSH is depleted, particularly mitochondria.

Mitochondrial and DNA protection. L-Ergothioneine accumulates in mitochondria, where it limits oxidative damage to mitochondrial DNA and supports membrane integrity during high-flux respiration. In aged tissue, this localization may slow the accumulation of mtDNA (mitochondrial DNA, the small genome inside mitochondria that is exposed to local oxidative stress) mutations and preserve respiratory complex function.

Anti-inflammatory and anti-senescence signaling. Cell and animal data show down-regulation of NF-κB (nuclear factor kappa B, a master regulator of inflammatory gene expression), reduced cytokine output (IL-6 (interleukin-6, a pro-inflammatory cytokine), TNF-α (tumor necrosis factor alpha, a pro-inflammatory cytokine)), and attenuation of senescence-associated secretory phenotype markers. The 2022 Apparoo and 2024 Chen reviews link these effects to the IIS (insulin/insulin-like growth factor signaling, a conserved nutrient-sensing pathway), SIRT6 (sirtuin 6, a NAD-dependent deacetylase involved in genomic stability), and mTOR (mechanistic target of rapamycin, a central nutrient-sensing kinase) pathways implicated in healthspan.

Hydrogen sulfide / persulfidation cross-talk. The 2025 Petrovic Cell Metabolism study identified a previously uncharacterized mechanism: L-Ergothioneine acts as an alternative substrate for CSE (cystathionine gamma-lyase, an enzyme that produces hydrogen sulfide) to generate hydrogen sulfide (H₂S), which then drives protein persulfidation (the addition of an SSH group to cysteine residues, a redox post-translational modification) at more than 300 protein targets, including activation of cytosolic glycerol-3-phosphate dehydrogenase and a downstream rise in NAD⁺ (nicotinamide adenine dinucleotide, a coenzyme central to mitochondrial metabolism).

Pharmacokinetics. Oral L-Ergothioneine is absorbed in the small intestine, taken up by erythrocytes via OCTN1, and reaches peak plasma concentrations approximately 1–2 hours after ingestion. The plasma half-life is short (a few hours), but the whole-body half-life is unusually long (estimated at one month or more) because OCTN1 captures circulating L-Ergothioneine and tissues retain it. Renal clearance is minimal (<4% of an absorbed dose); hepatic metabolism produces hercynine and S-methyl-ergothioneine as detectable metabolites. Cytochrome P450 (CYP) is not a major handler. Plasma and erythrocyte levels rise dose-dependently with chronic supplementation (3- to 16-fold reported in the 2025 Zajac trial at 10 mg and 25 mg daily for 16 weeks).

Selectivity and tissue distribution. L-Ergothioneine has no classical receptor target; effects are mediated by tissue accumulation and the redox/persulfidation chemistry described above. Highest concentrations are reported in erythrocytes, liver, kidneys, ocular lens, seminal fluid, and bone marrow; appreciable but lower levels reach the brain across the blood-brain barrier via OCTN1.

Where mechanisms compete. A subset of authors (notably Halliwell and Cheah) frame L-Ergothioneine principally as a tissue-protective antioxidant whose benefits should be largest where OCTN1 expression is high. Others (Filipovic and Petrovic) argue that the H₂S/persulfidation axis is the more relevant longevity mechanism. A skeptical view holds that human plasma at typical supplemental doses may not reach concentrations sufficient to perform meaningful peroxynitrite scavenging in vivo and that observational mortality associations may reflect confounding by overall diet quality. These positions remain unresolved.

Historical Context & Evolution

L-Ergothioneine was first isolated in 1909 by Charles Tanret from the ergot fungus Claviceps purpurea — the source of its name. Its presence in mammalian erythrocytes was demonstrated soon after, but for most of the twentieth century its biological role was considered uncertain because attempts to deplete it in animal models failed to produce a classical deficiency syndrome.

The pivotal change came in 2005, when Gründemann and colleagues identified OCTN1 (SLC22A4) as a high-affinity, selective transporter for L-Ergothioneine. The existence of a dedicated mammalian transporter for a compound that humans cannot synthesize implied evolutionary conservation for a function. This finding triggered a wave of mechanistic and clinical interest. Investigators including Barry Halliwell, Irwin Cheah, and Robert Beelman established that L-Ergothioneine is bioavailable from dietary mushrooms, accumulates in tissues exposed to oxidative stress, and falls in plasma after age sixty.

The 2018 PNAS review by Bruce Ames formalized a “longevity vitamin” framework in which L-Ergothioneine was named alongside PQQ, queuine, taurine, and several carotenoids as nutrients whose modest deficiency may imperceptibly accelerate diseases of aging. This framework moved L-Ergothioneine into mainstream supplement-and-longevity discussion.

Through 2020–2025, three lines of evidence converged. First, observational human cohorts (including the Wu 2022 memory-clinic cohort and large mortality cohorts cited in the May-Zhang 2025 review) reported associations between low blood L-Ergothioneine and cognitive decline, frailty, cardiovascular events, and all-cause mortality. Second, in vivo animal data demonstrated lifespan extension in Caenorhabditis elegans (Cheah 2013), Drosophila melanogaster (Pan 2022), and male mice (Katsube 2024). Third, the first long-duration human supplementation trials began to report results — the 2024 Yau pilot in 19 mild cognitive impairment subjects (NCT03641404) showed stabilized neurofilament light chain and improved verbal learning at 25 mg three times weekly for 12 months, and the 2025 Zajac dose-response RCT (randomized controlled trial, the gold-standard study design that randomly assigns participants to intervention or control) at 10 mg and 25 mg daily reported subjective memory and sleep-initiation gains at 25 mg.

Currently active questions include whether L-Ergothioneine should be repleted in dialysis populations (the active Stanford NCT06487546 trial), whether pharmacological doses translate observational mortality associations into causal benefits, and whether the H₂S/persulfidation mechanism (Petrovic 2025) should reframe the field away from a pure antioxidant model. The 2025 May-Zhang review and the 2025 Takhor systematic review together represent the current scientific synthesis: positioning L-Ergothioneine as a credible nutritional intervention whose causal claims still require confirmatory long-duration trials.

Expected Benefits

A dedicated search for L-Ergothioneine’s complete benefit profile was conducted across systematic reviews, narrative reviews, integrative-medicine references, and supplement compendia prior to drafting this section.

High 🟩 🟩 🟩

There are no L-Ergothioneine benefits that currently meet a “High” level of evidence in humans (multiple large RCTs or robust meta-analyses with consistent direction). Population mortality associations are observational and do not yet have RCT confirmation; the cognitive RCT signal is from small pilot trials. As the trial pipeline matures — particularly the PROMETHEUS (NCT07451496) and Stanford dialysis (NCT06487546) protocols — items may move into this category in subsequent reviews.

Medium 🟩 🟩

Stabilization of Neurodegeneration Biomarkers and Modest Memory Improvement in Mild Cognitive Impairment

L-Ergothioneine supplementation at 25 mg three times weekly for 12 months stabilized plasma NfL (neurofilament light chain, a blood biomarker of neuronal injury) levels and improved Rey Auditory Verbal Learning Test scores in adults aged 60+ with mild cognitive impairment (MCI, a transitional state between normal aging and dementia), while the placebo group showed rising NfL and no cognitive gain. The proposed mechanism is OCTN1-mediated brain accumulation, mitochondrial protection, and reduction of neuroinflammation. Evidence rests on the 2024 Yau pilot RCT (NCT03641404, n = 19), supported by the 2025 May-Zhang review and the 2025 Takhor systematic review of 19 studies.

Magnitude: Statistically significant improvement on Rey Auditory Verbal Learning Test versus placebo at 12 months; NfL stabilization versus placebo rise. Pilot scale, not yet replicated in large trials.

Improvement in Subjective Memory and Sleep Initiation in Older Adults with Memory Complaints

In a 16-week randomized, double-blind, placebo-controlled trial of 10 mg and 25 mg daily L-Ergothioneine in healthy older adults with subjective memory complaints (Zajac et al. 2025, summarized on Grokipedia and within the May-Zhang 2025 review), the 25-mg group showed dose-dependent improvements in subjective prospective memory and sleep initiation. Improvements in liver enzyme panels (ALT (alanine aminotransferase), AST (aspartate aminotransferase)) and increased peripheral blood telomere length were also reported. The proposed mechanisms are antioxidant tissue protection and circadian-relevant central effects. Plasma L-Ergothioneine rose 3- to 16-fold, confirming uptake.

Magnitude: Statistically significant improvements in subjective prospective memory and sleep initiation at 25 mg daily versus placebo; small absolute effect sizes in subjective measures.

Low 🟩

Lower All-Cause Mortality with Higher Dietary Mushroom Intake (Closest Population Proxy)

Higher mushroom consumption is associated with lower all-cause mortality risk (pooled risk ratio 0.94, 95% CI 0.91–0.98) in the 2021 Ba meta-analysis of 5 prospective cohorts including 601,893 participants. Mushrooms are the dominant dietary L-Ergothioneine source. The mechanism is consistent with antioxidant and anti-inflammatory tissue protection, but causal inference remains limited because mushroom intake is correlated with overall diet quality and lifestyle. Observational L-Ergothioneine plasma associations with mortality also exist but are not yet RCT-confirmed.

Magnitude: Approximately 6% relative reduction in all-cause mortality risk in those with the highest versus lowest mushroom intake.

Reduction in Postprandial Triglyceride Response After Mushroom-Derived L-Ergothioneine

A small randomized cross-over study in 10 healthy men reported attenuated postprandial triglyceride rise after meals containing 8 g and 16 g of mushroom powder (delivering L-Ergothioneine), versus a 0-g control. The proposed mechanism is acute antioxidant and possibly transporter-mediated effects on lipoprotein-lipase activity. Direct supplemental L-Ergothioneine has not been tested for this outcome.

Magnitude: Trend toward lower postprandial triglyceride excursion at 8 and 16 g mushroom doses; not powered to reach statistical significance.

Improved Cognitive and Mood Outcomes from Ergothioneine-Rich Mushroom Diets in Older Adults

The 2026 Cha et al. acute oyster mushroom RCT (Food & Function) and the completed 12-week chronic Pleurotus oyster mushroom intervention (NCT06846827) provide controlled-trial signal for cognitive, mood, anti-inflammatory, and metabolic improvements with L-Ergothioneine-rich mushrooms. The mechanism is consistent with central OCTN1-mediated uptake. Effects are smaller than for pharmaceutical cognitive enhancers and are entangled with other mushroom phytochemicals (β-glucans, phenolics).

Magnitude: Modest improvement in selected cognitive subtests and mood scales in the published trials; not quantified in standardized effect-size units in the available abstracts.

Improvement in Skin Brightness, Tone, and Elasticity in Adult Women

The completed NCT06886061 trial of DR. ERGO® 30 mg L-Ergothioneine capsules for 8 weeks in women aged 35–59 reported improvements in skin brightness, color tone, melanin, erythema, gloss, elasticity, and spots. The trial was sponsored by Shanghai EGT Synbio Group, an industry sponsor that produces L-Ergothioneine, which represents a direct conflict of interest in the evidence. The mechanism is consistent with cutaneous antioxidant accumulation and reduced UV-driven oxidative damage. The trial used a randomized, quadruple-blind, placebo-controlled design with 70 participants — industry sponsorship remains the primary limitation on causal inference.

Magnitude: Statistically meaningful improvements across instrument-measured skin parameters at 30 mg daily for 8 weeks; effect-size standardization is limited by trial design.

Reduction in Joint Range-of-Motion Limitation and Chronic Pain in a Nutraceutical Trial

A 2012 trial (Benson et al.) of an L-Ergothioneine-containing nutritional supplement reported improvements in joint range of motion and reduction in chronic pain. The mechanism is consistent with anti-inflammatory and antioxidant tissue effects. The supplement was a multi-ingredient formulation, limiting attribution to L-Ergothioneine itself.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cardiovascular Mortality Reduction Through Endothelial Antioxidant Tissue Protection

Observational data summarized in the May-Zhang 2025 review associate higher plasma L-Ergothioneine with lower cardiovascular mortality. Mechanism rests on endothelial OCTN1 expression and peroxynitrite scavenging. Direct controlled human cardiovascular outcome data are absent.

Renal Outcome Improvement in Dialysis-Dependent Kidney Failure

The active Stanford NCT06487546 RCT is testing whether 5–25 mg/day oral L-Ergothioneine repletes dialysis-related deficiency. Mechanism rests on OCTN1 expression in renal tissue and the documented depletion seen with hemodialysis and peritoneal dialysis. Outcome data are not yet available.

Lifespan Extension in Healthy Adult Humans

Lifespan extension has been demonstrated in C. elegans (Cheah 2013), Drosophila (Pan 2022), and male mice at 4–5 mg/kg/day (Katsube 2024). Whether the magnitude or even the direction translates to humans is uncertain; no human longevity outcome data exist.

Frailty Prevention and Mobility Preservation in Older Adults

Aged-rat data (Petrovic 2025) show enhanced exercise endurance, muscle mass, and vascularization with L-Ergothioneine supplementation through CSE-dependent persulfidation. Plasma L-Ergothioneine has been observed to fall with age and frailty. Direct human RCT data on frailty, sarcopenia (age-related loss of skeletal muscle mass and strength), or walking speed outcomes are absent.

Mechanistic and observational data summarized in the 2025 May-Zhang review suggest a role in cochlear oxidative protection. No human RCTs have tested this.

Liver Function Improvement (ALT, AST)

The 2025 Zajac dose-response RCT reported improvements in liver enzyme panels at 25 mg/day. The mechanism is consistent with hepatic OCTN1 expression and reduced oxidative hepatocyte damage. Replication in dedicated liver-disease populations is absent.

Benefit-Modifying Factors

  • OCTN1 (SLC22A4) polymorphism status: OCTN1 (the dedicated L-Ergothioneine transporter) genetic variants influence cellular uptake. The L503F variant has been associated with reduced transporter activity and inflammatory bowel disease risk; carriers may show smaller increases in tissue L-Ergothioneine for the same oral dose, though pharmacogenetically guided dosing is not yet validated.

  • Baseline plasma L-Ergothioneine status: Low baseline plasma L-Ergothioneine — common above age 60 and in dialysis, frailty, and cognitive-impairment populations — predicts larger absolute increases with supplementation and is the population in which clinical signal has been most consistent.

  • Sex differences: The 2024 Katsube longevity trial showed lifespan extension in male but not female mice at the dose tested. Direct sex-stratified human trial data are limited; available human trials have been mixed-sex without consistent sex-specific reporting.

  • Pre-existing health conditions: Mild cognitive impairment, subjective memory complaints, dialysis-dependent kidney failure, metabolic syndrome, and frailty are conditions in which signal-to-noise has been more favorable. Healthy younger adults with no clinical complaint show smaller measurable effects.

  • Age-related considerations: Plasma L-Ergothioneine declines after age sixty, so older adults typically show greater absolute repletion with supplementation. The strongest available human RCTs have enrolled adults aged 60+ specifically.

  • Dietary baseline (mushroom intake): Frequent mushroom consumers (porcini, oyster, shiitake, lion’s mane) have higher baseline plasma L-Ergothioneine; supplemental dose-response will be flatter in this group than in mushroom-avoiders.

  • Co-administration with concurrent antioxidants: Adequate vitamin C, vitamin E, selenium, and glutathione status supports the broader antioxidant network in which L-Ergothioneine operates. Severe deficiency in companion antioxidants may blunt the apparent supplemental effect.

  • Inflammatory state and gut health: Chronic systemic inflammation up-regulates OCTN1 expression in some tissues and modifies tissue distribution. Inflammatory bowel disease, in particular, is linked to OCTN1 variants and may alter pharmacokinetics.

Potential Risks & Side Effects

A dedicated search for the L-Ergothioneine side-effect profile was conducted across drug-reference sources (drugs.com, NIH MedlinePlus, WebMD, ConsumerLab, EFSA (European Food Safety Authority, the EU agency that evaluates food and supplement safety) Novel Food evaluations) and the published trial literature prior to this section.

High 🟥 🟥 🟥

There are no L-Ergothioneine adverse effects that currently meet a “High” level of evidence in humans. Across published RCTs and the EFSA novel-food evaluations, no consistent serious adverse-event signal has been documented at doses up to 30 mg/day for up to 12 months.

Medium 🟥 🟥

There are no L-Ergothioneine adverse effects that currently meet a “Medium” level of evidence in humans. The compound has been classified by EFSA as a novel food at doses up to 30 mg/day with no recurrent adverse-event signal across the trial literature.

Low 🟥

Generally Mild, Non-Specific Adverse Events

In the 2024 Yau RCT (NCT03641404, 25 mg three times weekly for 12 months in 19 subjects with mild cognitive impairment), no clinically significant changes in blood counts, kidney function, or liver function were observed. Across the broader L-Ergothioneine human trial set summarized in the 2025 May-Zhang review (≤25 mg/day for ≤16 weeks), reported adverse events were non-specific (occasional gastrointestinal complaints, headache) and did not exceed placebo rates. The mechanism is consistent with the compound’s well-established tolerability and short urinary excretion.

Magnitude: Reported in approximately 5–10% of subjects in published trials, similar to placebo rates.

Theoretical Pharmacokinetic Interaction at OCTN1 with Cationic Drugs

L-Ergothioneine is taken up via OCTN1, which also transports carnitine, gabapentin, verapamil, and ipratropium. The 2014 Toh study reported altered gabapentin pharmacokinetics in subjects on a mushroom-rich diet, attributed to OCTN1 substrate competition. The clinical magnitude of this interaction at typical supplement doses is small but is plausible at high doses.

Magnitude: Modest pharmacokinetic effects in mechanistic studies; clinical relevance not established at standard supplement doses.

Speculative 🟨

Long-Term Safety Above 30 mg/day or Beyond 12 Months

The longest published controlled human trials of L-Ergothioneine extend to 12 months at 25 mg three times weekly (Yau 2024) or 16 weeks at 25 mg/day (Zajac 2025). EFSA’s novel-food evaluation supports up to 30 mg/day. Safety at higher doses or for chronic use beyond one year has not been characterized in controlled trials.

Off-Target Effects on H₂S Signaling

The 2025 Petrovic mechanism — L-Ergothioneine acting as a CSE substrate for H₂S generation and protein persulfidation — implies a potential to alter dozens of downstream signaling targets. Whether chronic supplementation produces unintended persulfidation at off-target proteins, particularly in younger adults with intact H₂S signaling, is unresolved.

Effects in Pregnancy and Lactation

Direct trial data on supplemental L-Ergothioneine during pregnancy are absent. L-Ergothioneine is present in normal diet and accumulates in seminal fluid and presumably in placental and fetal tissues, but pharmacologic-dose safety has not been characterized; standard supplementation is generally avoided.

Effects in Children and Adolescents

No controlled-trial data exist in pediatric populations. Standard supplementation is generally avoided in this age group.

Pro-Oxidant Effects at Very High Concentrations

In vitro data at supraphysiologic concentrations have shown that some thione/thiol antioxidants can become pro-oxidant in the presence of redox-active metals. Whether this occurs with L-Ergothioneine at any dose realistically achievable orally in humans is unsupported by current evidence and remains a theoretical concern only.

Risk-Modifying Factors

  • OCTN1 (SLC22A4) genotype: Variants affecting transporter activity may alter both tissue uptake and the magnitude of any pharmacokinetic interaction with cationic drugs. Routine genotyping is not standard.

  • Concurrent OCTN1-substrate medications: Patients on gabapentin, verapamil, ipratropium, or carnitine supplementation may experience modest pharmacokinetic shifts; clinical relevance at standard L-Ergothioneine supplement doses is small but worth noting.

  • Pre-existing health conditions: Inflammatory bowel disease (linked to OCTN1 variants), end-stage renal disease (alters pharmacokinetics through dialysis-driven clearance), and active liver disease may shift the risk-benefit balance. The active Stanford dialysis trial (NCT06487546) is the most direct ongoing safety-and-efficacy assessment in a renal-failure population.

  • Sex differences: Limited sex-stratified human safety data are available; adverse-event reporting in published trials has not differed significantly by sex.

  • Baseline biomarker levels: Baseline plasma L-Ergothioneine, baseline liver enzymes (ALT, AST), and baseline kidney function (eGFR (estimated glomerular filtration rate, a measure of how well the kidneys filter blood)) all influence risk assessment. Subjects with markedly low baseline plasma L-Ergothioneine show larger absolute increases on supplementation and may be more sensitive to dose-related pharmacokinetic perturbation; baseline hepatic and renal markers help establish a safety reference for chronic users.

  • Age-related considerations: Older adults (60+) constitute the population in which most L-Ergothioneine RCTs have been conducted. No age-specific safety signal has emerged at doses up to 30 mg/day.

  • Pregnancy and lactation: Insufficient safety data on pharmacologic doses; standard supplementation is generally avoided.

  • Manufacturing-quality and source provenance: L-Ergothioneine sold as a supplement is now produced primarily by precision fermentation (Mironova MironHealth, ErgoActive, MoZuo Bio, and similar). Older mushroom-extract products may vary substantially in purity and content; third-party verification reduces this concern.

Key Interactions & Contraindications

  • OCTN1 substrate medications: Gabapentin (an anticonvulsant and neuropathic-pain medication that is also an OCTN1 substrate), verapamil (a calcium-channel blocker), ipratropium (an inhaled anticholinergic for chronic obstructive pulmonary disease and asthma), and carnitine (a conditionally essential nutrient also transported by OCTN1): theoretical pharmacokinetic competition at the transporter. Severity: monitor; clinical relevance is low at standard supplemental doses but worth noting in patients on tightly-titrated regimens.

  • Cationic drugs metabolized through organic cation transporters more broadly: Metformin (a biguanide antidiabetic medication; primarily an OCT1/OCT2 substrate, with limited OCTN1 affinity), cimetidine (an H2-receptor antagonist that inhibits multiple cation transporters): theoretical interaction is mechanistic only; no clinically actionable interaction has been documented at standard L-Ergothioneine doses. Severity: monitor.

  • Anticoagulants and antiplatelet agents: No documented pharmacokinetic interaction. Theoretical antioxidant-mediated effects on platelet function have been raised but are not clinically supported. Severity: minor caution at high doses.

  • Over-the-counter medications: No documented OTC (over-the-counter, available without a prescription) medication interaction has been characterized at standard L-Ergothioneine supplement doses.

  • Supplements with additive or competing OCTN1 affinity: L-Carnitine (an OCTN2 substrate with some OCTN1 affinity), acetyl-L-carnitine: theoretical mild competition. Severity: minor; co-administration is common in practitioner protocols without reported issue.

  • Supplements with overlapping antioxidant and redox actions: N-acetylcysteine (NAC), glutathione, alpha-lipoic acid, selenium, vitamin C, vitamin E: complementary rather than competing actions; co-administration is the norm. Severity: not contraindicated.

  • Mushroom-derived products: Concentrated medicinal mushroom extracts (lion’s mane, oyster, shiitake, porcini, Hericium erinaceus) are dietary L-Ergothioneine sources. Severity: not contraindicated; users should account for cumulative intake when also taking isolated L-Ergothioneine.

  • Other interventions: Hemodialysis and peritoneal dialysis substantially deplete plasma and erythrocyte L-Ergothioneine through filtration and adsorption to the dialyzer membrane; the active Stanford NCT06487546 trial is testing repletion strategies in this group.

  • Populations to avoid or use with caution: pregnancy at any gestational age and lactation (insufficient data); pediatric populations under 18 years of age (insufficient data outside narrow clinical contexts); active moderate-to-severe inflammatory bowel disease (Crohn’s disease or ulcerative colitis with active flare or Mayo endoscopic subscore ≥2) at the time of OCTN1-targeted dosing decisions (mechanistically relevant but not contraindicated); known hypersensitivity to L-Ergothioneine or any excipient (rare but possible); end-stage renal disease (eGFR <15 mL/min/1.73 m²) or dialysis-dependent kidney failure outside an active clinical-trial framework.

Risk Mitigation Strategies

  • Start at the low end of the supplement range (5–10 mg/day) and reassess at 8–16 weeks: the 2024 Yau and 2025 Zajac trials used 10–25 mg/day with full safety and clear plasma uptake; lower doses produce smaller pharmacokinetic perturbation and align with EFSA novel-food precedent. Mitigates: any unexpected idiosyncratic adverse effect; OCTN1 substrate competition.

  • Use precision-fermentation-derived L-Ergothioneine over poorly characterized mushroom extracts for supplemental dosing: modern production yields high-purity, third-party-tested material; mushroom extracts vary by species, batch, and growing conditions. Mitigates: contamination risk; uncertain dose; off-target compounds in extract.

  • Account for dietary mushroom intake when setting a supplement dose: frequent porcini, oyster, shiitake, or lion’s mane consumers may already meet baseline L-Ergothioneine adequacy; supplementation can be adjusted accordingly. Mitigates: unnecessary supplementation; inflated cumulative dose.

  • Separate dosing of L-Ergothioneine from gabapentin, verapamil, or ipratropium by 2–3 hours where feasible: reduces transporter-level pharmacokinetic competition for tightly titrated regimens. Mitigates: gabapentin and other OCTN1-substrate dose-response variability.

  • Avoid initiation in pregnancy, lactation, and pediatric populations outside clinical-trial settings: absence of safety data is the principal concern. Mitigates: unknown developmental risks.

  • For dialysis-dependent kidney failure, consider supplementation only within an active clinical-trial framework or specialist-supervised protocol: the population is the focus of an active RCT (NCT06487546), and individualized dosing relative to dialysis schedule has not been fully characterized. Mitigates: dose miscalibration in a high-pharmacokinetic-variability group.

  • Discontinue and consult a clinician at the first sign of any unexplained symptom suggestive of pharmacokinetic interaction (gabapentinoid sedation, verapamil-related hypotension, ipratropium under-response): these are theoretical OCTN1-related concerns. Mitigates: drug-level shifts in tightly titrated regimens.

  • Use products with USP, NSF, or Informed-Sport approval where available; otherwise prefer reputable brands sourcing from Mironova MironHealth, ErgoActive, MoZuo Bio, or equivalent fermentation suppliers: third-party testing reduces contamination risk and confirms label claim. Mitigates: adulteration; under-dosing.

  • Do not exceed 30 mg/day without explicit clinical supervision and documented baseline labs: EFSA’s novel-food precedent supports doses up to 30 mg/day; higher doses lack systematic safety characterization. Mitigates: unknown long-term high-dose effects.

Therapeutic Protocol

L-Ergothioneine protocols vary by indication; the following reflects practice in the integrative-medicine and longevity-clinic context, anchored to the published trial evidence.

  • Standard longevity-and-cognitive dosing: 5–25 mg/day taken once daily, ideally with food. The 2024 Yau (25 mg three times weekly), 2025 Zajac (10 mg or 25 mg daily), and Life Extension consumer products (5 mg, 25 mg) span this range. Higher doses are not consistently more effective in available trials.

  • Skin-aging dosing: 30 mg/day for 8–12 weeks, as used in NCT06886061. Often combined with topical vitamin C, niacinamide, or sunscreen for additive skin-quality effects.

  • Mild cognitive impairment dosing: 25 mg three times weekly per the Yau 2024 protocol, continued for at least 6–12 months before judging effect; should be supervised by a clinician familiar with cognitive-decline workups.

  • Renal-failure repletion (clinical-trial context only): 5–25 mg/day per the active Stanford NCT06487546 protocol; not recommended for self-administration in dialysis patients outside a trial or specialist supervision.

  • Best time of day: flexible. The compound is well retained, and there is no documented time-of-day advantage. Many users take it with breakfast or a midday meal alongside other antioxidants.

  • Half-life and dosing strategy: plasma half-life is short (a few hours), but tissue half-life is long (estimated at one month or more) due to OCTN1 retention. Once-daily dosing is standard; missed doses do not require makeup dosing.

  • Single vs. split dosing: there is no demonstrated advantage to split dosing at typical supplemental doses. A single daily capsule is standard.

  • Genetic considerations: OCTN1 (SLC22A4) variants — particularly L503F — may modify tissue uptake. Routine genotyping is not standard. Direct-to-consumer panels rarely report this variant; pharmacogenetically guided dosing is not yet validated.

  • Sex-based considerations: the 2024 Katsube mouse longevity data showed effect in males only at the dose tested. Whether this translates to humans is unknown; current human trials have been mixed-sex with similar plasma uptake by sex.

  • Age considerations: the strongest human evidence is in adults aged 60 and above, the population in which baseline plasma L-Ergothioneine is depressed and the relative repletion is largest. Younger adults will show smaller absolute change in plasma levels.

  • Baseline biomarkers: plasma L-Ergothioneine measurement is available through specialty laboratories and may help distinguish responders from non-responders; sleep diary, subjective memory questionnaires, and skin-quality measures are appropriate where indication-specific.

  • Pre-existing health conditions: dialysis-dependent kidney failure, inflammatory bowel disease (OCTN1-relevant), and known hypersensitivity warrant additional caution. Pregnancy and lactation are general avoidances.

Discontinuation & Cycling

  • Duration: L-Ergothioneine can be used either short-term (8–16 weeks for skin and acute-cognitive applications) or long-term (12+ months as in the Yau MCI trial); the longest controlled trials extend to 12 months at 25 mg three times weekly without a documented safety signal.

  • Withdrawal effects: no clinically significant withdrawal syndrome has been recognized. Plasma and erythrocyte levels decline gradually over weeks to months after discontinuation, reflecting the compound’s long tissue half-life.

  • Tapering protocol: not required; abrupt discontinuation is safe and produces no rebound effect.

  • Cycling for tolerance or efficacy: no formal cycling protocol has been validated. Because tissues retain L-Ergothioneine for weeks after discontinuation, intermittent dosing schedules (e.g., 25 mg three times weekly per Yau 2024) may reasonably substitute for daily dosing without loss of effect; this hypothesis has not been directly tested.

  • Reassessment of indication: if used for 6–12 months without subjective benefit on the primary indication (cognitive complaints, skin quality, sleep initiation), reassessment is appropriate before extending. Higher doses are not consistently more effective and have not been systematically characterized for safety beyond 30 mg/day.

Sourcing and Quality

  • Form: the pure L-enantiomer (L-Ergothioneine) is the natural and biologically active form; D-Ergothioneine and racemic mixtures are not standard. Modern precision-fermentation production yields high-purity L-isomer material.

  • Production method: prefer precision-fermentation-derived L-Ergothioneine (e.g., engineered Escherichia coli or Saccharomyces cerevisiae expressing fungal Egt1/Egt2 genes; commercialized as Mironova MironHealth, ErgoActive, MoZuo Bio, and equivalent). These deliver consistent dose with documented purity, in contrast to mushroom extracts that vary by species, batch, and processing.

  • Purity and certifications: prefer products carrying USP, NSF Certified for Sport, Informed-Sport, or ConsumerLab approval. Many longevity-positioned brands publish third-party test results verifying L-Ergothioneine content.

  • Dose accuracy: ConsumerLab’s testing of mushroom-extract supplements has historically identified marked variability in actual L-Ergothioneine content; fermentation-derived isolate products typically meet label claim more reliably.

  • Excipients: prefer minimal-excipient capsule forms; verify against unnecessary fillers and adulterants.

  • Reputable brands: brands with clean records and verified L-Ergothioneine content include Life Extension (Mega L-Ergothioneine, Essential Youth L-Ergothioneine), Double Wood Supplements, NOW Foods, Real Mushrooms (mushroom-extract version), and Pure Encapsulations. ConsumerLab’s review of L-Ergothioneine and mushroom supplements provides independent testing data.

  • Cost benchmark: L-Ergothioneine is moderately priced (approximately $0.50–$2.00 per 5–25 mg capsule from reputable brands). Pure-isolate fermentation-derived products are typically more expensive than mushroom-extract alternatives but provide standardized dose.

  • Mushroom-extract vs. isolated L-Ergothioneine: both can deliver the compound. Whole-mushroom or mushroom-extract supplements provide additional bioactives (β-glucans, ergosterol, phenolics) but with less precise L-Ergothioneine dose; isolated L-Ergothioneine provides defined dose without the matrix.

Practical Considerations

  • Time to effect: plasma and erythrocyte levels rise within 1–2 weeks of daily supplementation; tissue accumulation continues over 8–16 weeks. Cognitive and clinical effects in published trials emerged at 4–16 weeks (Zajac) and at 6–12 months (Yau). Skin-quality effects emerged at 8 weeks (NCT06886061).

  • Common pitfalls: using mushroom-extract products with no verified L-Ergothioneine content (especially mycelium-on-grain products that mycologist Jeff Chilton has identified as containing little to no actual ergothioneine); assuming higher doses produce proportionally larger benefits (the available trials cap at 25–30 mg/day with consistent signal); discontinuing prematurely before tissue levels equilibrate (3–4 months); ignoring concurrent OCTN1-substrate medications in tightly titrated regimens.

  • Regulatory status: in the United States, L-Ergothioneine is sold as a dietary supplement under DSHEA (the Dietary Supplement Health and Education Act, the U.S. law governing supplement marketing and labeling); not FDA-approved for any specific indication; GRAS (Generally Recognized As Safe, an FDA designation for substances considered safe under intended food use) status applies to dietary intake from mushrooms. The European Food Safety Authority granted novel-food authorization for synthetic L-Ergothioneine at doses up to 30 mg/day. Japan permits it as a food ingredient. Canada permits it as a Natural Health Product.

  • Cost and accessibility: widely available without prescription at moderate cost in North America, Europe, and Japan. Pure precision-fermentation isolate is more expensive than mushroom extracts but provides defined dose. No exceptional accessibility concerns.

Interaction with Foundational Habits

  • Sleep: Direct interaction. The 2025 Zajac dose-response RCT reported improved subjective sleep initiation at 25 mg/day in older adults with subjective memory complaints. The proposed mechanism is central antioxidant accumulation and reduced neuroinflammation supporting circadian regulation. Practical considerations: take with breakfast or earlier in the day if sleep initiation is the goal; no documented sleep-disrupting effect.

  • Nutrition: Direct and bidirectional interaction. L-Ergothioneine is a dietary nutrient; mushrooms are the principal source, with porcini (highest), oyster, shiitake, and lion’s mane providing meaningful intake. A diet containing 100 g of dried oyster mushroom delivers approximately 4 mg L-Ergothioneine per gram. Cooking does not substantially destroy L-Ergothioneine. Soil practices (regenerative versus tillage-intensive) affect L-Ergothioneine in non-mushroom plant foods at the margin (per Beelman 2022). Combining a mushroom-rich diet with isolated supplementation is reasonable; cumulative intake should be tracked.

  • Exercise: Indirect interaction. Aged-rat data (Petrovic 2025) show enhanced exercise endurance and muscle vascularization with L-Ergothioneine through CSE-dependent persulfidation and cGPDH activation. The 2026 Wazny review specifically frames L-Ergothioneine plus exercise as a candidate cognitive-aging combination. The 2013 Zembron-Lacny shiitake-extract trial in eccentric exercise reported attenuated oxidative damage. No direct evidence supports L-Ergothioneine as a performance enhancer in healthy active adults.

  • Stress management: Indirect interaction. Chronic stress elevates oxidative load and inflammation, conditions in which OCTN1 is up-regulated and tissue L-Ergothioneine demand is greater. Stress management is foundational; L-Ergothioneine does not substitute for it, but the available data are consistent with greater apparent benefit in stressed and inflamed states than in optimally healthy states.

Monitoring Protocol & Defining Success

Baseline testing establishes a reference point before initiating L-Ergothioneine, particularly for older adults, dialysis patients, and those with cognitive or skin-aging indications.

Ongoing monitoring cadence: subjective indication-specific assessment (memory questionnaire, skin photography, sleep diary) at baseline, 4 weeks, and 16 weeks; plasma L-Ergothioneine if specialty testing is available, at baseline and 12 weeks; standard safety panel (CBC (complete blood count, a standard hematology panel), comprehensive metabolic panel including liver enzymes and creatinine) at baseline and 6–12 months for chronic users; reassessment of indication at 6–12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma L-Ergothioneine >5 µmol/L (target; varies by lab) Confirms absorption and uptake Specialty laboratory test; rises 3- to 16-fold on 10–25 mg/day; useful for distinguishing OCTN1 high- vs low-uptake phenotypes
Erythrocyte L-Ergothioneine Higher than plasma; lab-specific reference Long-term tissue exposure marker Erythrocytes accumulate L-Ergothioneine to supraplasma levels; the most stable in vivo reservoir
Subjective memory or PSQI Baseline reference; improvement at 16 weeks Tracks cognitive and sleep response PSQI = Pittsburgh Sleep Quality Index, a validated 0–21 sleep questionnaire; useful for indication-specific tracking
Rey Auditory Verbal Learning Test (RAVLT) Baseline reference; improvement at 12 months Tracks verbal learning response in mild cognitive impairment Validated neuropsychological instrument; primary outcome in the Yau 2024 mild cognitive impairment trial
Plasma neurofilament light chain (NfL) Stable or decreasing (lower preferred) Marker of neuronal injury Serum-based test; rising NfL reflects neurodegeneration; stabilization is the Yau 2024 secondary signal
ALT, AST ALT <25 U/L (men), <19 U/L (women); AST <25 U/L Liver function safety and possible improvement signal Conventional reference range broader; functional medicine targets the lower half; Zajac 2025 reported improvement at 25 mg/day
Creatinine and eGFR >60 mL/min/1.73 m² Kidney function safety eGFR = estimated glomerular filtration rate, an indicator of kidney function; standard chemistry panel; relevant for OCTN1-dependent renal handling
Complete blood count (CBC) Within normal range General hematologic safety The Yau 2024 trial confirmed no change at 25 mg three times weekly for 12 months
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L Inflammatory state context Conventional reference <3.0 mg/L; functional-medicine target <1.0 mg/L; modulates OCTN1 expression and tissue demand
Skin imaging (where indication is skin-aging) Baseline reference; improvement at 8 weeks Tracks skin brightness, melanin, erythema, elasticity NCT06886061 instrument-based assessment; baseline, 4 weeks, 8 weeks

Qualitative markers to track:

  • Subjective memory and cognitive clarity over the dosing period
  • Sleep-initiation latency and overall sleep quality
  • Skin tone, brightness, and elasticity (where this is the indication)
  • Mood and stress reactivity
  • Energy, exercise tolerance, and recovery from exertion
  • Any new symptoms suggestive of OCTN1-substrate interaction (gabapentin under- or over-response, verapamil-related hypotension)
  • General gastrointestinal tolerance

Emerging Research

Conclusion

L-Ergothioneine occupies a distinctive place in the longevity and supplement landscape: a diet-derived sulfur amino acid that humans cannot make but selectively retain through a dedicated transporter. The strongest signals in humans to date are stabilization of a neuronal-injury blood marker and modest improvement in verbal learning in older adults with mild cognitive impairment, gains in subjective memory and sleep initiation in older adults with memory complaints, improvements in skin brightness and elasticity in middle-aged women, and a population-level mortality association with the closest dietary proxy. Outside these contexts the case rests on observational, mechanistic, and animal data.

The safety picture is favorable. Across published trials at doses up to 30 mg/day for up to twelve months, no serious or recurrent adverse-event signal has emerged, and European regulators have granted novel-food authorization at this dose range. Practical concerns are the variable content of mushroom-extract products (especially mycelium-on-grain formats) and theoretical pharmacokinetic interaction with medications sharing the dedicated transporter. The evidence base also includes manufacturer-sponsored skin-benefit data (notably a Shanghai EGT Synbio Group trial), a direct industry conflict of interest worth weighing alongside academic and clinician-led evidence.

For health- and longevity-oriented adults, the overall picture frames L-Ergothioneine as a tractable, well-tolerated nutritional intervention with a credible mechanistic foundation, an expanding but still-young human evidence base, and the largest measurable signal in older adults with depleted baseline status.

Top - Benefits - Risks - Protocol